A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

Pilot Web-based Study of Functional Status, Symptom Palliation and Quality of Life Benefits Associated With Darbepoetin Alfa (Aranesp®) Administration in Anemic Patients With Cancer.

This is a web-based pilot study to evaluate the association between the treatment of anemia with darbepoetin alfa (aranesp) and the clinical benefits in symptom palliation, improved functional status and quality of life in patients with cancer. The feasibility of web-based assessments and data capture will be evaluated.

Study Overview

• Status: Completed
• Conditions: Cancer; Anemia
• Intervention / Treatment: Biological: darbepoetin alfa

Detailed Description

Anemia associated with lung cancer and chemotherapy is an important factor effecting patient symptoms, functional status, and overall quality of life (Groopman and Itri 1999; Langer, Choy et al. 2002). Darbepoetin alfa (Aranesp®) has demonstrated a significant effect upon ameliorating chemotherapy-induced anemia in lung cancer (Vansteenkiste, Pirker et al. 2002; Vansteenkiste, Poulsen et al. 2002). This trial is designed to evaluate the association between the treatment of anemia with darbepoetin alfa and direct electronic capture of clinical benefits in cancer-related symptoms, functional status and overall quality of life. This trial uses a secure web-based design to capture the patient-associated symptoms, functional status and quality of life. This novel secure web-based system was selected to improve the efficiency and quality of clinical data capture. If our hypothesis is correct, treatment with darbepoetin alfa will be associated with improved palliation of cancer-related symptoms, improved functional status, and result in overall benefits to the patient's health-related quality of life. The development of a web-based system to directly capture patient-related symptoms, functional status and quality of life will permit us in the future to conduct a national or international trial addressing the effects of darbepoetin alfa on these factors. If our hypothesis is incorrect, it may be that these parameters are not affected by the correction of anemia with darbepoetin alfa or the measures are not sensitive enough to detect these differences. A notable finding would be a clearly defined improvement in symptom palliation, functional status, and quality of life associated with darbepoetin alfa therapy.

• Study Type: Interventional
• Enrollment (Actual): 43
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • New Hampshire
    • Lebanon, New Hampshire, United States, 03756
      • Norris Cotton Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Confirmation of non-myeloid cancer (myeloproliferative disorders will be excluded).
• Hemoglobin concentration ≤ 11.0 g/dL.
• Age ≥ 18 years.
• Karnofsky performance status ≥ 60%.
• Anemia predominantly due to cancer or chemotherapy.
• Serum creatinine concentration ≤ 2.0 mg/dL.
• Total serum bilirubin ≤ 1.5 times the upper limit of normal.
• Nutritional status adequate to provide vitamin B12 and folate within the normal limits.
• Capacity to complete the web-based functional status, symptom and quality of life assessments.
• Ability to give informed consent.

Exclusion Criteria:

• Untreated symptomatic primary or metastatic cancer involving the central nervous system.
• History of clinically significant iron deficiency.
• Greater than two red blood cell transfusions within 2 weeks of registration or any red blood cell transfusion within 7 days of registration.
• Received epoetin alfa or darbepoetin alfa therapy within 3 weeks prior to randomization.
• History of a seizure disorder.
• Unstable angina, congestive heart failure (New York Heart Association > class II or known ejection fraction < 40%) or uncontrolled cardiac arrhythmias.
• Uncontrolled hypertension defined as a diastolic blood pressure > 100 mmHg.
• Clinical evidence of active infection or inflammatory diseases such as rheumatoid arthritis. Subjects with active rheumatoid arthritis are excluded.
• Known positive test for human immunodeficiency virus infection.
• Known primary hematological disorder which could cause anemia such as sickle cell anemia.
• Pregnant or breast-feeding.
• Not using adequate contraception if of childbearing potential.
• Known hypersensitivity to any recombinant mammalian-derived product.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: 1; Darbepoetin alfa 200 mcg with escalation to 300 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11)	Biological: darbepoetin alfa; The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience <1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations >13.0 g/dL.; Other Names: aranesp
Active Comparator: 2; darbepoetin alfa 300 mcg with escalation to 500 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 3 weeks for 12 weeks (weeks 1, 4, 7, and 10)	Biological: darbepoetin alfa; The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience <1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations >13.0 g/dL.; Other Names: aranesp

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
A secure web-based assessment of cancer-related symptoms (LCSS), functional status (SF-36), and quality of life (FACT-An and PFS) will be obtained every 2 weeks (weeks 3, 5, 7, 9, 11, and 13).	every 2 weeks (weeks 3, 5, 7, 9, 11, and 13)

Secondary Outcome Measures

Outcome Measure	Time Frame
A blood sample will be obtained to evaluate hemoglobin concentrations every 2 weeks (weeks 3, 5, 7, 9, 11, and 13).	every 2 weeks (weeks 3, 5, 7, 9, 11, and 13)
A blood sample will be obtained to evaluate plasma cytokines every 4 weeks (weeks 5, 9, and 13).	every 4 weeks (weeks 5, 9, and 13)

Collaborators and Investigators

• Sponsor: Dartmouth-Hitchcock Medical Center
• Collaborators: Amgen
• Investigators: Principal Investigator: James R Rigas, MD, Norris Cotton Cancer Center

Study record dates

Study Major Dates

• Study Start: October 1, 2003
• Primary Completion (Actual): August 17, 2007
• Study Completion (Actual): August 17, 2007

Study Registration Dates

• First Submitted: September 8, 2005
• First Submitted That Met QC Criteria: September 8, 2005
• First Posted (Estimate): September 12, 2005

Study Record Updates

• Last Update Posted (Actual): September 23, 2021
• Last Update Submitted That Met QC Criteria: September 17, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Keywords: Cancer; Quality of life; Anemia; Darbepoetin alfa; Aranesp; Web-based
• Additional Relevant MeSH Terms: Hematinics; Darbepoetin alfa
• Other Study ID Numbers: D-0341

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No